Center-Authored Papers

Filters: Keyword is Fever  [Clear All Filters]
A
Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly PJ, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J et al..  2011.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.. European journal of cancer (Oxford, England : 1990). 47(1):8-32. Abstract
Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL.  2002.  G-CSF as prophylaxis of febrile neutropenia in SCLC.. Expert opinion on pharmacotherapy. 3(9):1273-81. Abstract
B
Berrington WR, Jerome KR, Cook L, Wald A, Corey L, Casper C.  2009.  Clinical correlates of herpes simplex virus viremia among hospitalized adults.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 49(9):1295-301. Abstract
Blume HK, Li CI, Loch CM, Koepsell TD.  2008.  Intrapartum fever and chorioamnionitis as risks for encephalopathy in term newborns: a case-control study.. Developmental medicine and child neurology. 50(1):19-24. Abstract
C
Clark OAC, Lyman G, Castro AA, Clark LGO, Djulbegovic B.  2003.  Colony stimulating factors for chemotherapy induced febrile neutropenia.. The Cochrane database of systematic reviews. (3):CD003039. Abstract
Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B.  2005.  Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(18):4198-214. Abstract
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ et al..  2011.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(8):914-32.
Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S et al..  2005.  Myeloid growth factors clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 3(4):540-55.
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.  1991.  Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.. The New England journal of medicine. 325(3):164-70. Abstract
Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J et al..  2009.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(1):64-83.
Crawford J, Dale DC, Lyman GH.  2004.  Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.. Cancer. 100(2):228-37. Abstract
H
Hirsch BR, Lyman GH.  2012.  Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.. PharmacoEconomics. 30(6):497-511. Abstract
K
Kuderer NM, Dale DC, Crawford J, Lyman GH.  2007.  Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(21):3158-67. Abstract
Kuderer NM, Lyman GH.  2011.  Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.. Journal of the National Cancer Institute. 103(12):910-3.
L
Laskey RA, Poniewierski MS, Lopez MA, Hanna RK, Secord AA, Gehrig PA, Lyman GH, Havrilesky LJ.  2012.  Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.. Gynecologic oncology. 125(3):625-30. Abstract
Lyman GH.  2006.  Withholding antibiotics from patients with febrile neutropenia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(7):1221-2;authorreply1222-3.
Lyman GH, Lyman CG, Sanderson RA, Balducci L.  1993.  Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy.. Journal of the National Cancer Institute. 85(6):488-93. Abstract
Lyman GH, Michels SL, Reynolds MW, Barron R, Smoyer Tomic K, Yu J.  2010.  Risk of mortality in patients with cancer who experience febrile neutropenia.. Cancer. 116(23):5555-63. Abstract
Lyman GH, Kuderer N, Greene J, Balducci L.  1998.  The economics of febrile neutropenia: implications for the use of colony-stimulating factors.. European journal of cancer (Oxford, England : 1990). 34(12):1857-64. Abstract
Lyman GH, Kuderer NM.  2003.  Cost effectiveness of myeloid growth factors in cancer chemotherapy.. Current hematology reports. 2(6):471-9. Abstract
Lyman GH, Williams CC, Preston D, Goldman A, Dinwoodie WR, Saba H, Hartmann R, Jensen R, Shukovsky L.  1981.  Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy.. The American journal of medicine. 70(6):1222-9. Abstract
Lyman GH, Kuderer NM, Balducci L.  1998.  Economic impact of granulopoiesis stimulating agents on the management of febrile neutropenia.. Current opinion in oncology. 10(4):291-6. Abstract
Lyman GH, Delgado DJ.  2003.  Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.. Cancer. 98(11):2402-9. Abstract